Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.1007/s40273-025-01482-3

Título: The monetary value of a statistical life in the context of atherosclerotic cardiovascular disease
Fecha de publicación: 29-mar-2025
Editorial: Springer
Cita bibliográfica: PharmacoEconomics, 2025
ISSN: Print: 1170-7690
Electronic: 1179-2027
Resumen: Aim This study aims to estimate the value of a statistical life (VSL) in the context of atherosclerotic cardiovascular disease (ASCVD) in Spain using a contingent valuation/standard gamble (CV/SG) chained approach.MethodsThe study employed a two-stage preference elicitation method that combined contingent valuation and a modified standard gamble technique. Specifically, willingness-to-pay and willingness-to-accept values were obtained for two health states depicting hypothetical outcomes following cardiovascular events. Subsequently, relative utility losses for the health states were derived using a modified standard gamble framing two risky choices. Chaining these elicited values allowed for VSL calculation without requiring direct valuation of small mortality risk reductions. The study was conducted through in-person interviews with a representative sample of 412 Spanish adults selected by stratified quotas.Results The estimated VSL range is from 1.59 to 2.06 million euros. Minor differences emerge between VSL figures on the basis of each of the two health states. These VSL estimates for ASCVD are congruent with the recent update of the official VSL estimated for Spain in the context of road traffic accidents, though the upper limit of the range is slightly higher (almost 9%).ConclusionsVSL estimates align with existing ranges in other European countries, particularly in the context of road safety, where a significant portion of existing studies is concentrated. Comparisons with other contexts, involving cardiovascular diseases, also lend support to the estimates presented here.
Autor/es principal/es: Martínez Pérez, Jorge Eduardo
Sánchez Martínez, Fernando Ignacio
Abellán Perpiñán, José María
Pascual Figal, Domingo
Versión del editor: https://link.springer.com/article/10.1007/s40273-025-01482-3
URI: http://hdl.handle.net/10201/152916
DOI: https://doi.org/10.1007/s40273-025-01482-3
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 13
Derechos: info:eu-repo/semantics/openAccess
Atribución-NoComercial 4.0 Internacional
Descripción: © 2025, The Author(s). This manuscript version is made available under the CC-BY-NC 4.0 license http://creativecommons.org/licenses/by-nc/4.0/ This document is the Published Manuscript, version of a Published Work that appeared in final form in PharmacoEconomics. To access the final edited and published work see https://doi.org/10.1007/s40273-025-01482-3
Aparece en las colecciones:Artículos

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
s40273-025-01482-3.pdf835,27 kBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons